Words by GOLD newsdesk
Moderna has become the latest member of the Association of the British Pharmaceutical Industry (ABPI), the organisation has announced.
Following its inclusion into the UK BioIndustry Association in September 2022, this new membership is testament to the US-based RNA giant’s long-term commitment to expand its footprint in the UK pharmaceutical space. Key to its involvement in the region will be a new state-of-the-art vaccine research, development and manufacturing facility.
“Moderna is committed to delivering the greatest possible impact to people through mRNA medicines. We look forward to working with the ABPI and our fellow member companies to build on the already strong UK environment for science and innovation,” said Darius Hughes, UK General Manager, Moderna, who also highlighted the importance of this alliance in supporting its long-term aims in the UK.
Commenting on the alliance, Richard Torbett, Chief Executive, ABPI, said: “I’m delighted to welcome Moderna into membership as a world-leading pharmaceutical company that can help bring the UK closer to realising its ambitions to be a leading global centre for life sciences. With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.”
The ABPI positions itself as a representative for companies investing in the discovery of the medicines of the future, and members must adhere to the standards set out in the organisation’s code of practice.
